Faculty of 1000 evaluation for Conventional vs. extended-cycle oral contraceptives on the quality of sexual life: comparison between two regimens containing 3 mg drospirenone and 20 µg ethinyl estradiol.

2011 ◽  
Author(s):  
Chiara Simonelli ◽  
Roberta Rossi
Keyword(s):  
Oral Contraceptives ◽  
Ethinyl Estradiol ◽  
Sexual Life ◽  
Extended Cycle

Conventional vs. Extended-Cycle Oral Contraceptives on the Quality of Sexual Life: Comparison between Two Regimens Containing 3mg Drospirenone and 20µg Ethinyl Estradiol

2011 ◽  
Vol 8 (5) ◽  
pp. 1478-1485 ◽  
Author(s):  
Salvatore Caruso ◽  
Marco Iraci Sareri ◽  
Carmela Agnello ◽  
Mattea Romano ◽  
Lucia Lo Presti ◽  
...  
Keyword(s):  
Oral Contraceptives ◽  
Ethinyl Estradiol ◽  
Sexual Life ◽  
Extended Cycle

Effects of combined oral contraceptives on the sexuality and quality of life of women

GYNECOLOGY ◽  
2019 ◽  
Vol 21 (2) ◽  
pp. 66-70
Author(s):  
Rushanya I Gabidullina ◽  
Elvira I Galimyanova ◽  
Rufat R Bagirli ◽  
Anastasiya M Sharapova
Keyword(s):  
Quality Of Life ◽  
Oral Contraceptives ◽  
Sexual Desire ◽  
Control Method ◽  
Sexual Interest ◽  
Sexual Life ◽  
Cochrane Library ◽  
High Concentration ◽  
The Impact

Aim. Examine the impact of combined oral contraceptive on sexuality and the quality of women’s life. Materials and methods. The article presents a review of Electronic literature databases MEDLINE, PubMed, EMBASE, Cochrane Library and Elibrary. Results. Since its first introduction in the 1960s, hormonal contraception has been widely used as a highly effective birth control method. However, the hormonal components of oral contraceptives affect the neuroendocrine system of women, exerting various effects on mood, libido, on sexuality and quality of life in general. Based on literature data the effect of contraception on sexuality, the physiological and emotional state of women are various. It is known that the hormonal supplementation of sexual desire is associated with ovarian hormones. At the same time, a high concentration of estrogen and testosterone receptors has been determined in the hypothalamus, which controls sexual function and mood. The mechanisms to implement the effects of androgen and progesterone on sexual desire are ambiguous. It was found a positive relationship between a sexual interest, sexual response, sexual fantasy, frequency of sexual intercourse and a testosterone level. At the same time, it is known that estradiol can increase the ability of women to orgasmic response and sexual satisfaction by acting on specific brain structures. Conclusion. The effect of contraception on women’s sexual life is an important factor when choosing a method of contraception and an integral part in the obstetrician-gynecologist’s practice, which requires further research in this direction.

Decreased Levels of Histidine-Rich Glycoprotein (HRG) and Increased Levels of Free Plasminogen in Women on Oral Contraceptives Low in Estrogen

1982 ◽  
Vol 48 (03) ◽  
pp. 283-285 ◽  
Author(s):  
Jørgen Jespersen ◽  
Cornelis Kluft
Keyword(s):  
Oral Contraceptives ◽  
Ethinyl Estradiol ◽  
Relative Increase ◽  
Normal Group ◽  
Plasma Samples ◽  
Normal Women ◽  
Made In

SummaryDeterminations by immunologic methods of histidine-rich glycoprotein (HRG) and plasminogen, were made in plasma samples collected during one normal or hormone induced cycle in 15 young, normal women and in 11 women using oral contraceptives with 30 μg ethinyl estradiol and 150 μg levo-norgestrel. The hormone group showed an increase in plasminogen level to about 150% of normal, while the concentration of HRG was decreased to about 75% of normal. This resulted in a considerable relative increase in the concentration of free plasminogen in the hormone group (calculated from the equilibrium: HRG·plasminogen ⇌ HRG + plasminogen, using KD = 1.0 μM), representing a doubling of that in the normal group. Hence, more plasminogen is available for binding to fibrin and activation in the hormone group.

Does Infliximab Short Infusion have a Beneficial Impact on the Quality of Life in Patients with Inflammatory Bowel Diseases? A Single Centre Prospective Evaluation

2015 ◽  
Vol 24 (2) ◽  
pp. 165-170 ◽  
Author(s):  
Mariabeatrice Principi ◽  
Giuseppe Losurdo ◽  
Rosa Federica La Fortezza ◽  
Pasquale Lopolito ◽  
Rosa Lovero ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Inflammatory Bowel Diseases ◽  
Adverse Reactions ◽  
Severe Disease ◽  
Sexual Life ◽  
Necrosis Factor Alpha ◽  
Short Infusion ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Background & Aims: Infliximab (IFX) is an anti-tumor necrosis factor alpha agent used in inflammatory bowel diseases (IBD) therapy. Usually, it is administered over a 2-hour intravenous infusion. However, shortening the infusion duration to 1 hour has proved to be feasible and safe. In the present study we evaluated whether shortening the IFX infusion could affect the patients' quality of life (QoL) compared to the standard protocol.Methods: Subjects affected by IBD receiving IFX were prospectively recruited. The main criterion to shorten the infusion was the absence of IFX-related adverse reactions during the previous three 2-h infusions. For each patient, demographic, clinical and anthropometric data were collected. A questionnaire investigating their overall/job/social/sexual QoL was administered. Ordinal regression was performed with odds ratios (OR) for significant independent variables.Results: Eighty-one patients were included (46 with ulcerative colitis - UC, 35 with Crohn's disease - CD). Sixteen received the 2-h infusion due to previous adverse reactions, and the remaining 65 underwent the 1-h schedule. Shortening the infusion to 1 hour determined a better QoL (OR=0.626). However, the QoL was negatively influenced by age (OR=1.023), female sex (OR=2.04) and severe disease activity (OR=7.242). One-hour IFX infusion induced a better outcome on work (OR=0.588) and social (OR=0.643) QoL. Long-standing disease was correlated with a slightly better sexual QoL (OR=0.93). Conversely, older age (OR=1.046), severe clinical score (OR=15.579), use of other immunomodulators (OR=3.693) and perianal CD (OR=3.265) were related to an unsatisfactory sexual life. The total number of infusions (OR=0.891), proctitis (OR=0.062) or pancolitis (OR=0.1) minimized the perception of infusion-related side effects.Conclusion: The 1-h short infusion improves overall, social and job QoL, so that, when indicated, it should be recommended.

Was the Quality of Sexual Life Affected during the COVID-19 Pandemic?

2021 ◽  
pp. 1-16
Author(s):  
İbrahim Özlü ◽  
Zeynep Karaman Özlü ◽  
Tülay Kilinç ◽  
Zühal Yetiş Demir ◽  
Serap Ejder Apay ◽  
...  
Keyword(s):  
Sexual Life

scholarly journals Male Circumcision Due to Phimosis as the Procedure That Is Not Only Relieving Clinical Symptoms of Phimosis But Also Improves the Quality of Sexual Life

2021 ◽  
Vol 9 (2) ◽  
pp. 100315
Author(s):  
Mateusz Czajkowski ◽  
Katarzyna Czajkowska ◽  
Karolina Zarańska ◽  
Alicja Giemza ◽  
Jakub Kłącz ◽  
...  
Keyword(s):  
Male Circumcision ◽  
Clinical Symptoms ◽  
Sexual Life

Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care

2008 ◽  
Vol 23 (8) ◽  
pp. 561-566 ◽  
Author(s):  
Ronette L. Kolotkin ◽  
Patricia K. Corey-Lisle ◽  
Ross D. Crosby ◽  
Hong J. Kan ◽  
Robert D. McQuade
Keyword(s):  
Quality Of Life ◽  
Clinical Symptoms ◽  
Clinical Trial Data ◽  
Standard Of Care ◽  
Random Regression ◽  
Sexual Life ◽  
Baseline Body Mass Index ◽  
Meaningful Change ◽  
Related Quality

AbstractBackgroundThis is a secondary analysis of clinical trial data collected in 12 European countries. We examined changes in weight and weight-related quality of life among community patients with schizophrenia treated with aripiprazole (ARI) versus standard of care (SOC), consisting of other marketed atypical antipsychotics (olanzapine, quetiapine, and risperidone).MethodFive-hundred and fifty-five patients whose clinical symptoms were not optimally controlled and/or experienced tolerability problems with current medication were randomized to ARI (10–30 mg/day) or SOC. Weight and weight-related quality of life (using the IWQOL-Lite) were assessed at baseline, and weeks 8, 18 and 26. Random regression analysis across all time points using all available data was used to compare groups on changes in weight and IWQOL-Lite. Meaningful change from baseline was also assessed.ResultsParticipants were 59.7% male, with a mean age of 38.5 years (SD 10.9) and mean baseline body mass index of 27.2 (SD 5.1). ARI participants lost an average of 1.7% of baseline weight in comparison to a gain of 2.1% by SOC participants (p < 0.0001) at 26 weeks. ARI participants experienced significantly greater increases in physical function, self-esteem, sexual life, and IWQOL-Lite total score. At 26 weeks, 20.7% of ARI participants experienced meaningful improvements in IWQOL-Lite score, versus 13.5% of SOC participants. A clinically meaningful change in weight was also associated with a meaningful change in quality of life (p < 0.001). A potential limitation of this study was its funding by a pharmaceutical company.ConclusionsCompared to standard of care, patients with schizophrenia treated with aripiprazole experienced decreased weight and improved weight-related quality of life over 26 weeks. These changes were both statistically and clinically significant.

Sign in / Sign up

Export Citation Format

Share Document